Structure-Based Design and Synthesis of Potent and Selective KRAS G12D Inhibitors
The KRAS G12D mutation subtype is present in over 40% of pancreatic ductal adenocarcinomas (PDAC), making this an important drug target. WuXi AppTec scientists recently contributed to a research article in ACS Med. Chem. Letters describing the optimization of a series of potent and selective KRAS G12D inhibitors through a structure-based drug design approach. The authors identify a lead compound, ERAS-5024, which demonstrates potent in vitro antiproliferative activities in a panel of cell lines harboring the G12D mutation and exhibits robust in vivo efficacy with regression activity in a PDAC-CDX model.
Check out our extensive panel of RAS-related assays and services by clicking HERE.